EXACT Therapeutics AS ("EXACT-Tx') held its Annual General Meeting onJune 1st 2021 at 1300hrs CET. According to the record included as Appendix 1, 16,257,225 shares of a total of 29,967,750 issued shares and votes, corresponding to 54.25% of the total number of voting shares in the Company, were represented at the general meeting. All proposed resolutions were approved. Please find enclosed the minutes of the meeting including appendices. For further information, please contact: DrRafiq Hasan , CEO rafiq@exact-tx.com About EXACT-Tx EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com
Click here for more information
© Oslo Bors ASA, source